🔗 Share this article

Given that the US proceeds with unprecedented revisions to its vaccination recommendations, an unexpected name has emerged somewhat surprisingly: Tracy Beth Høeg, an American of Danish descent physician and epidemiologist who initially gained attention by expressing skepticism about coronavirus vaccinations throughout the pandemic and has focused upon potential fatalities after COVID-19 vaccination in her short time at the FDA.

Proposed Shifts to Childhood Immunization Program

Public health authorities had intended to unveil radical changes to the childhood vaccination calendar recently, synchronizing the US with the Danish immunization schedule, according to reports – a substantial departure that would place the US out of step with much of the international standard with insufficient data for improved outcomes. This reveal has been postponed until the coming year.

Rather than the director of the vaccine center, Høeg is scheduled to speak at the meeting. She was just designated temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to run the office this year.

Consolidating Power at the Agency

This interim role could signify a strengthened alliance between the drug and vaccine centers as Høeg and Prasad strengthen their influence at the regulatory agency – and it signals a increased emphasis upon reevaluating long-standing immunizations at the FDA.

Dr. Høeg has repeatedly called for ending certain childhood vaccine recommendations in the US to become more like the Danish model, a society with universal health coverage and a number of inhabitants about the population of the state of Wisconsin.

So far public appearances, she has persisted in emphasizing on vaccination policy – usually the purview of Prasad, chief of the FDA’s CBER – as opposed to medication approval.

Doubts Over Expertise

Høeg has no obvious track record in drug development, oversight or leadership, which has been typical for previous heads of the biologics center. She has worked at the FDA as a top consultant to the commissioner and CBER since spring.

“She doesn’t seem to have the requisite experience” for leading the pharmaceutical oversight division, said Dr. Jonathan Howard. “She’s never run a clinical trial. She lacks experience in running a large organization. She lacks background in pharmaceutical oversight.”

Former heads of the center would “grasp laws and regulations and the research of pharmaceutical innovation”, commented Dr. Janet Woodcock. “Clearly, she has not acquired the kind of background that prior appointees who led the center have had.”

CDER has an immense workload at the agency, the former commissioner stated.

“Everybody just focuses on the innovative therapies, but the generic drug division clears thousands of generic medications. There is also a biosimilars program, over-the-counter program and so forth, and every single one must be managed,” she said. “The thing you don’t keep your eye on, that is precisely what that I always told people is going to come back to haunt you.”

Additionally, a major administrative aspect to the job, which manages more than 5,000 employees. “It is a massive management job, if you execute it properly,” Woodcock added.

Official Statement and Controversial Programs

When asked about inquiries about Dr. Høeg's qualifications and whether this appointment signifies greater collaboration among agency officials on immunizations, a spokesperson said that the “concerns stem from inaccurate presumptions”.

“Her resume matches the functions of her role,” the official said, citing the months Høeg spent counseling the agency head on “medication safety and regulatory science, including computerized risk analysis and vaccine surveillance”.

As acting director, Dr. Høeg inherits the commissioner’s recently launched priority voucher program, a contentious expedited medication authorization process that allegedly concerned her predecessors. “By what process are these drugs being picked for this expedited pathway? Who makes the choices?” Dr. Howard questioned. “There’s a lot of lack of transparency happening at the agency right now.”

Broadly speaking, he said, “the agency appears to be shifting towards less stringent regulations of all drugs, with the exception of shots.”

Documented Track Record on Immunizations

Regarding immunizations, Høeg has a more established, if concerning, history, critics said. She released a study using unverified crowd-sourced reports to assess the rate of heart inflammation following Covid vaccination. She advised the state of Florida top health official Joseph Ladapo, who was said to have modified findings to imply COVID-19 vaccinations are more dangerous than they are.

Included in her “wish list” for the new administration encompassed changing guidelines for new vaccines and halting “non-essential” immunizations, she remarked following the vote on a podcast. At the FDA, Høeg has according to sources floated the idea of barring young men from receiving COVID-19 vaccinations.

“She’s an complete ideologue who begins with her preconceived notions and works backwards to retrofit the data in a highly misleading, fraudulent fashion,” Howard argued.

Gaining Influence and a “Revenge Tour”

Dr. Høeg aligned with other dissenters, {like|